BATON ROUGE, La., Oct. 21, 2013 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global developer, manufacturer and marketer of highly engineered specialty chemicals and services, announced that it has expanded the kilo lab at its FDA-registered cGMP active pharmaceutical ingredient (API) production facility in South Haven, Michigan. Production using the new, expanded kilo lab is expected in January 2014.
The expanded kilo lab will allow Albemarle to better focus on customers' needs for smaller quantities of material specifically produced to cGMP guidelines. Supporting the company's overall pharmaceutical custom synthesis offering, the expansion will enable Albemarle to address customer requirements throughout the entire life-cycle of their product, beginning from early stage clinical development to full-scale commercial production. The kilo lab production unit will operate within South Haven's cGMP standards and will be suitable for production of API products.
Albemarle Fine Chemistry Services is equipped with the assets and experience to fulfill demand requirements at all program phases, from grams and low kilogram amounts to 50+ MT scale projects. The Company specializes in enabling customers to go to market in an efficient and fully compliant manner by providing comprehensive process development, scale-up and validation capabilities followed by seamless transition into commercial-scale production.
Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer, and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services. The Company is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts and Fine Chemistry. Corporate Responsibility Magazine selected Albemarle to its prestigious "100 Best Corporate Citizens" list for 2010, 2011 and 2013. Albemarle employs approximately 4,200 people and serves customers in approximately 100 countries. Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, Regulation G reconciliations, SEC filings, and other information regarding the Company, its businesses and the markets we serve.
Albemarle's Fine Chemistry Services (FCS) division is an innovative, full-service provider of fine chemicals to the world's leading companies across the pharmaceutical, agrichemical, and specialty materials markets. Albemarle's FCS division helps global customers complete hundreds of successful projects through a powerful combination of proven chemistry expertise, game-changing process development, high-quality custom manufacturing and exceptional service. From innovative R&D to commercial-scale production, Albemarle's FCS division delivers the knowledge, experience, resources, creativity and service you need to move products to market faster and accelerate your business. To learn more about Albemarle's FCS division, please visit www.albemarle.com/fcs.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.
SOURCE Albemarle Corporation